title: Inhibitory effect of hericenone B from Hericium erinaceus on collagen-induced platelet aggregation.
abstract: Platelet aggregation in the blood vessel causes thrombosis. Therefore, inhibitors of platelet aggregation promise to be preventive or therapeutic agents of various vascular diseases, including myocardial infarction and stroke. In the present study, we found that hericenone B had a strong anti-platelet activity and it might be a novel compound for antithrombotic therapy possessing a novel mechanism. Prior to this study, we examined anti-platelet aggregation activity of ethanol extracts of several species of mushrooms, and found that extract of Hericium erinaceus potently inhibited platelet aggregation induced by collagen. Therefore, we first fractionated the ethanol extract of H. erinaceus to identify the active substances. The anti-platelet activity of each fraction was determined using washed rabbit platelets. As a result, an active component was isolated and identified as hericenone B. Hericenone B selectively inhibited collagen-induced platelet aggregation, but it did not suppress the aggregation induced by U46619 (TXA₂ analogue), ADP, thrombin, or adrenaline. Furthermore, hericenone B did not inhibit arachidonic acid- or convulxin (GPVI agonist)-induced platelet aggregation. Therefore, hericenone B was considered to block collagen signaling from integrin α2/β1 to arachidonic acid release. Moreover, we found that collagen-induced aggregation was inhibited by hericenone B in human platelets, similar to in rabbit platelets.
authors.affiliation: Department of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Mori
authors.forename: Haruhisa
authors.initials: H
authors.lastname: Kikuchi
authors.forename: Yutaro
authors.initials: Y
authors.lastname: Obara
authors.forename: Masaya
authors.initials: M
authors.lastname: Iwashita
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Azumi
authors.forename: Satomi
authors.initials: S
authors.lastname: Kinugasa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Inatomi
authors.forename: Yoshiteru
authors.initials: Y
authors.lastname: Oshima
authors.forename: Norimichi
authors.initials: N
authors.lastname: Nakahata
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D016718:Arachidonic Acid; D001487:Basidiomycota / Q000737:chemistry*; D001688:Biological Products / Q000737:chemistry / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D003094:Collagen / Q000378:metabolism*; D003435:Crotalid Venoms; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000302:isolation & purification / Q000494:pharmacology*; D037181:Lectins, C-Type; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000302:isolation & purification / Q000494:pharmacology*; D011817:Rabbits; D015398:Signal Transduction / Q000187:drug effects; D013917:Thrombin / Q000494:pharmacology; D013927:Thrombosis / Q000517:prevention & control
chemical_list: D001688:Biological Products; D003435:Crotalid Venoms; D007211:Indoles; D037181:Lectins, C-Type; D010975:Platelet Aggregation Inhibitors; C557360:hericenone B; D016718:Arachidonic Acid; C028890:convulxin; D000244:Adenosine Diphosphate; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D003094:Collagen; D013917:Thrombin; D004837:Epinephrine